Krystal Biotech (KRYS) Profit After Tax (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Profit After Tax data on file, last reported at $55.9 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 54.03% year-over-year to $55.9 million; the trailing twelve-month figure through Mar 2026 stood at $225.0 million (up 77.63% YoY), and the FY2025 full-year result was $204.8 million, up 129.74% from the prior year.
• Profit After Tax advanced to $55.9 million in Q1 2026, from $51.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $80.6 million in Q3 2023 to a low of -$50.0 million in Q1 2022.
• A 5-year average of $13.1 million and a median of $15.6 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 215.99% in 2022 and soared 3796.24% in 2025, its largest moves.
• Tracing KRYS's Profit After Tax over 5 years: stood at -$32.1 million in 2022, then surged by 126.04% to $8.3 million in 2023, then surged by 444.92% to $45.5 million in 2024, then advanced by 13.02% to $51.4 million in 2025, then gained by 8.82% to $55.9 million in 2026.
• Business Quant data shows KRYS's Profit After Tax at $55.9 million in Q1 2026, $51.4 million in Q4 2025, and $79.4 million in Q3 2025.